Market Newsdesk

 Conference call to be held today at 9:00 a.m. EST

Sunrise, Florida, Nov. 12, 2020 (GLOBE NEWSWIRE) — – Nano Dimension Ltd. (Nasdaq: NNDM), a leading Additively Manufactured Electronics (AME)/PE (Printed Electronics) provider, today announced financial results for the third quarter ended September 30, 2020. 

Nano Dimension reported revenues of $438,000 for the third quarter of 2020. The Company ended the quarter with a cash and deposits balance of $45,720,000 (including short and long-term unrestricted bank deposits), while net loss for the third quarter was $20,716,000 and negative adjusted EBITDA for the third quarter was $3,373,000.

“These are not disappointing results per se,” said Yael Sandler, Chief Financial Officer of Nano Dimension. “As we have projected starting April 2020, the reduced revenues in 2020 as a result of the COVID-19 pandemic being prolonged and re-emerging crises, were in fact expected to be lower than we have achieved. Actually, in APAC, the revenues have seemed to already start a modest recovery in the fourth quarter of 2020. We believe that the United States is still in a process of downswing of capital expenditures under the influence of the COVID-19 pandemic, and European prospective customers are sinking back toward a commercial stand still, under the effects of its second wave. As the market stagnation is prolonged, understandably hesitant and/or careful customers tend to delay investments in breakthrough, new prototyping and fabrication technologies of unique Hi-PEDs™ (High Performance Electronic Devices). While the phenomena are clear and present, they are probably temporary,” concluded Ms. Sandler.

Mr. Yoav Stern, Chief Executive Officer and President of Nano Dimension commented: “The expectation of our market growth has not changed, and we believe that this is a interim delay. We expect the mid-term slow-down effect to act like a “sling shot” once COVID-19 will start to phase-out.¹ The pressure of the trade struggles with the East is already creating an interest for reshoring electronic manufacturing. Nano Dimension technology is ideally positioned as our 3D printing machines for Hi-PEDs™ are an environmentally friendly non-polluting fabrication and overnight prototyping methodology, fitting for setting up fabrication facilities in-house on the western continents.”

Mr. Stern concluded: “As per above, we are not judging, at this point, our success by quarterly revenues. That will come later. Nano Dimension operates along an expected fail-safe investment model, where upside may resemble Biotech investments, but, contrary to those, downside in case of failure at any stage is somewhat hedged and hence protected. We have sold 60 machines already, mostly to leading blue chip defense, academic and commercial organizations worldwide. It is reasonable to assume that in case a decision is made at the right time, a sale of our existing business at improving multiples, as per future stages, is a doable task. On the upside, an exponential growth post COVID-19 may lead us to an unprecedented leadership role. Our future “Stages” as defined at this point (subject to adjustment based on advancement in R&D) are: Stage I: Materials at Commercial-Specs, Stage II: Materials at Industrial-Specs, Stage III: Materials at Mil-Specs, Stage IV: Low Production Volume 3D-System, Stage V: Medium Production Volume 3D-System.” 

¹
IDTechEX (2019): The total market for 3D printed electronics will be worth $2.3 billion by 2029 and will be dominated by the professional PCB prototyping market segment. The educational and industrial production market segments will continue to grow steadily.
The market for professional PCB prototyping is currently growing very rapidly, almost entirely due to market leader Nano Dimension, and has already overtaken the consumer and education. This growth will slow but this market segment will become the largest by 2020.
DataM Intelligence (2018): Analysts predict 3D printed electronics will be the next high-growth application for product innovation: 2017 3D printed electronics market size is estimated at $176 million, expected to reach $592 million in 2021 and up to $2.4 billion by 2025.
Transparency Market Research (2018): The global 3D printed electronics market was valued at US$ 137.1 million in 2017 and is expected to expand at a CAGR of 44.46% from 2018 to 2026, reaching $ 3.9 billion by the end of the forecast period. 
  
Third Quarter 2020 Financial Results

• Total revenues for the third quarter of 2020 were $438,000, compared to $288,000 in the second quarter of 2020, and $2,243,000 in the third quarter of 2019. The decrease is attributed to continuing delays in identified transactions of DragonFly systems, which the Company primarily attributes to the impact of COVID-19.

• Research and development (R&D) expenses for the third quarter of 2020 were $2,556,000, compared to $1,895,000 in the second quarter of 2020, and $2,083,000 in the third quarter of 2019. The increase compared to both the second quarter of 2020 and the third quarter of 2019 is attributed to an increase in payroll and related expenses, as the Company is temporarily shifting resources from sales and marketing to product enhancements, as well as an increase in share-based payment expenses.

• Sales and marketing (S&M) expenses for the third quarter of 2020 were $2,475,000, compared to $930,000 in the second quarter of 2020, and $1,217,000 in the third quarter of 2019. The increase compared to both the second quarter of 2020 and the third quarter of 2019 is attributed to an increase in share-based payment expenses.

• General and administrative (G&A) expenses for the third quarter of 2020 were $14,805,000, compared to $908,000 in the second quarter of 2020, and $799,000 in the third quarter of 2019. The increase compared to both the second quarter of 2020 and the third quarter of 2019 is attributed to an increase in share-based payment expenses. In the third quarter of 2020, we recognized share-based payment expenses of approximately $13,617,000 with respect to warrants granted to our CEO and President and to one of our directors.    

• Net loss for the third quarter of 2020 was $20,716,000, or $0.45 per share, compared to $8,265,000, or $0.27 per share, in the second quarter of 2020, and $4,308,000, or $1.21 per share, in the third quarter of 2019. The increase compared to both the second quarter of 2020 and the third quarter of 2019 is mainly attributed to share-based payment expenses of approximately $15,852,000 that were recognized in the third quarter of 2020. 

Nine Months Ended September 30, 2020 Financial Results

• Total revenues for the nine months ended September 30, 2020 were $1,428,000, compared to $5,093,000 in the nine months ended September 30, 2019. The decrease is attributed to less sales of DragonFly systems, which the Company primarily attributes to the impact of COVID-19.

• R&D expenses for the nine months ended September 30, 2020 were $6,153,000, compared to $6,557,000 in the nine months ended September 30, 2019. The decrease resulted primarily from a decrease in payroll and related expenses and materials expenses, partially offset by an increase in share-based payment expenses.        

• S&M expenses for the nine months ended September 30, 2020 were $4,224,000, compared to $4,088,000 in the nine months ended September 30, 2019. The increase is mainly attributed to an increase in share-based payment expenses, partially offset by a decrease in marketing and advertising expenses.         

• G&A expenses for the nine months ended September 30, 2020 were $16,748,000, compared to $2,389,000 in the nine months ended September 30, 2019. The increase is mainly attributed to an increase in share-based payment expenses. In the nine months ended September 30, 2020, we recognized share-based payment expenses of approximately $13,617,000 with respect to warrants granted to our CEO and President and to one of our directors.         

• Net loss for the nine months ended September 30, 2020 was $31,055,000, or $1.11 per share, compared to $6,972,000, or $2.08 per share, in the nine months ended September 30, 2019. The increase is mainly attributed to share-based payment expenses of approximately $16,797,000 that were recognized in the nine months ended September 30, 2020. 

Balance Sheet Highlights

 

• Cash and cash equivalents, together with short and long-term bank deposits totaled $45,720,000 as of September 30, 2020, compared to $3,894,000 as of December 31, 2019. The increase compared to December 31, 2019, mainly reflects proceeds received from the sale of American Depositary Shares representing the Company’s ordinary shares, less cash used in operations, during the nine months ended September 30, 2020. 

• Shareholders’ equity totaled $52,691,000 as of September 30, 2020, compared to $11,602,000 as of December 31, 2019.  

Conference call information

The Company will host a conference call to discuss these financial results today, November 12, 2020, at 9:00 a.m. EST (4:00 p.m. IDT). Investors interested in participating are invited to register for the conference call here: https://dpregister.com/sreg/10149108/db3a251138. Dial-in numbers, including a local Israeli number and instructions, will be provided upon registration. U.S. Dial-in Number: 1-844-695-5517, International Dial-in Number: 1-412-902-6751, Israel Toll Free Dial-in Number: 1-80-9212373. Please request the “Nano Dimension NNDM call” when prompted by the conference call operator. The conference call will also be webcast live from the Investor Relations section of Nano Dimension’s website at http://investors.nano-di.com/events-and-presentations.

For those unable to participate in the conference call, there will be a replay available from a link on Nano Dimension’s website at http://investors.nano-di.com/events-and-presentations.

About Nano Dimension

Nano Dimension (Nasdaq: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices. They necessitate iterative development, IP safety, fast time-to-market and device performance gains, thereby mandating AME for in-house, rapid prototyping and production. Nano Dimension machines serve cross-industry needs by depositing proprietary consumable conductive and dielectric materials simultaneously, while concurrently integrating in-situ capacitors, antennas, coils, transformers and electromechanical components, to function at unprecedented performance. Nano Dimension bridges the gap between PCB and semiconductor integrated circuits. A revolution at the click of a button: From CAD to a functional high-performance AME device in hours, solely at the cost of the consumable materials. For more information, please visit www.nano-di.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Nano Dimension’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release. For example, Nano Dimension is using forward-looking statements when it discusses the expected impact of the COVID-19 pandemic and the expected growth once it starts to phase out, the expected recovery of its revenues, including in APAC, its investment model, potential sale at improving multiples and its future stages. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano Dimension’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Nano Dimension is not responsible for the contents of third party websites. 

NANO DIMENSION INVESTOR RELATIONS CONTACT

Yael Sandler, CFO | [email protected]

Unaudited Consolidated Statements of Financial Position as at

		September 30,								December 31,
		2019				2020				2019(*)
(In thousands of USD)
Assets
Cash and cash equivalents			5,466				21,020				3,894
Bank deposits							16,300
Restricted deposits			31				60				31
Trade receivables			2,348				568				1,816
Other receivables			458				661				570
Inventory			3,620				4,032				3,543
Total current assets			11,923				42,641				9,854
Bank deposits			–				8,400				–
Restricted deposits			359				379				377
Property plant and equipment, net			4,979				4,735				4,743
Right of use asset			4,054				2,478				2,673
Intangible assets			5,404				4,633				5,211
Total non-current assets			14,796				20,625				13,004
Total assets			26,719				63,266				22,858
Liabilities
Trade payables			487				842				850
Other payables			3,448				4,420				3,575
Total current liabilities			3,935				5,262				4,425
Liability in respect of government grants			811				883				1,044
Lease liability			3,476				1,829				2,089
Liability in respect of warrants and rights of purchase			7,575				2,601				3,698
Total non-current liabilities			11,862				5,313				6,831
Total liabilities			15,797				10,575				11,256
Equity
Share capital			5,559				66,252				6,441
Share premium and capital reserves			64,023				77,535				65,202
Treasury shares			(1,509	)			(1,509	)			(1,509	)
Presentation currency translation reserve			1,431				1,431				1,431
Accumulated loss			(58,582	)			(91,018	)			(59,963	)
Total equity			10,922				52,691				11,602
Total liabilities and equity			26,719				63,266				22,858

(*) The December 31, 2019 balances were derived from the Company’s audited annual financial statements. 

Unaudited Consolidated Statements of Profit or Loss and Other Comprehensive Income


(In thousands of USD, except per share amounts) 
  

		For the Nine-Month Period Ended September 30,								For the Three-Month Period Ended September 30,								For the Year ended December 31,
		2019				2020				2019				2020				2019(*)
Revenues			5,093				1,428				2,243				438				7,070
Cost of revenues			3,183				890				1,224				301				4,312
Cost of revenues – amortization of intangible			579				579				193				193				772
Total cost of revenues			3,762				1,469				1,417				494				5,084
Gross profit (loss)			1,331				(41	)			826				(56	)			1,986
Research and development expenses, net			6,557				6,153				2,083				2,556				8,082
Sales and marketing expenses			4,088				4,224				1,217				2,475				5,469
General and administrative expenses			2,389				16,748	(**)			799				14,805	(**)			3,270
Operating loss			(11,703	)			(27,166	)			(3,273	)			(19,892	)			(14,835	)
Finance income			6,923				171				100				41				8,765
Finance expense			2,192				4,060				1,135				865				2,283
Total comprehensive loss			(6,972	)			(31,055	)			(4,308	)			(20,716	)			(8,353	)
Basic loss per share (after 1:50 reverse split effective June 29, 2020)			(2.08	)			(1.11	)			(1.21	)			(0.45	)			(2.38	)

(*) The December 31, 2019 balances were derived from the Company’s audited annual financial statements.

(**) The general and administrative expenses include share-based payment expenses of approximately $14,547 in the nine months ended September 30, 2020, and approximately $13,977 in the third quarter of 2020. 

Consolidated Statements of Changes in Equity (Unaudited)


(In thousands of USD)

		Share capital				Share premium and capital reserves				Treasury shares				Presentation currency translation reserve				Accumulated loss				Total equity
For the nine months ended September 30, 2020:
Balance as of January 1, 2020			6,441				65,202				(1,509	)			1,431				(59,963	)			11,602
Issuance of ordinary shares, net			55,512				(9,743	)			—				—				—				45,769
Conversion of convertible notes			2,013				(78	)			—				—				—				1,935
Exercise of warrants and options			2,286				2,867				—				—				—				5,153
Share-based payments			—				19,287				—				—				—				19,287
Net loss			—				—				—				—				(31,055	)			(31,055	)
Balance as of September 30, 2020			66,252				77,535				(1,509	)			1,431				(91,018	)			52,691
For the three months ended September 30, 2020:
Balance as of July 1, 2020			66,236				61,748				(1,509	)			1,431				(70,302	)			57,604
Exercise of options			16				(16	)			—				—				—				—
Share-based payments			—				15,803				—				—				—				15,803
Net loss			—				—				—				—				(20,716	)			(20,716	)
Balance as of September 30, 2020			66,252				77,535				(1,509	)			1,431				(91,018	)			52,691

Non-IFRS measures

The following is a reconciliation of EBITDA and adjusted EBITDA to net loss:

		For the Nine-Month Period Ended September 30,								For the Three-Month Period Ended September 30,								For the Year ended December 31,
		2019				2020				2019				2020				2019
Net loss			6,972				31,055				4,308				20,716				8,353
Interest income			–				(52	)			–				(52	)			–
Depreciation and amortization			2,038				1,958				702				667				2,666
EBITDA			(4,934	)			(29,149	)			(3,606	)			(20,101	)			(5,687	)
Non-cash financial expense (income), net			(6,424	)			3,941				566				876				(8,175	)
Share-based payments			367				16,797				174				15,852				439
Adjusted EBITDA			(10,991	)			(8,411	)			(2,866	)			(3,373	)			(13,423	)

EBITDA

EBITDA is a non-IFRS measure and is defined as earnings before interest expense (income), income tax, depreciation and amortization. We believe that EBITDA, as described above, should be considered in evaluating the Company’s operations. EBITDA facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures (affecting interest expenses (income), net), and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively) and EBITDA is useful to an investor in evaluating our operating performance because it is widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to the items mentioned above.

Adjusted EBITDA is a non-IFRS measure and is defined as earnings before non-cash financial expense (income), income tax, depreciation and amortization, and share based payments. Non-cash financial expenses (income), net include exchange rate differences, finance expense (income) for revaluation of liability in respect of government grants, finance expense (income) for revaluation of liability in respect of warrants and rights to purchase, as well as changes in lease liability. We believe that Adjusted EBITDA, as described above, should also be considered in evaluating the Company’s operations. Like EBITDA, Adjusted EBITDA facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures (affecting non-cash financial expenses (income), net), and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively), as well as from share-based payment expenses, and Adjusted EBITDA is useful to an investor in evaluating our operating performance because it’s widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to non-cash items, such as expenses related to share based payments.

EBITDA and Adjusted EBITDA do not represent cash generated by operating activities in accordance with IFRS and should not be considered alternatives to net income (loss) as indicators of our operating performance or as measures of our liquidity. These measures should be considered in conjunction with net income (loss) as presented in our consolidated statements of profit or loss and other comprehensive income. Other companies may calculate EBITDA and Adjusted EBITDA differently than we do.

LAS VEGAS, Nov. 12, 2020 (GLOBE NEWSWIRE) — Asia Broadband Inc. (AABB), through its wholly owned subsidiary Asia Metals Inc., announced today that the Company has signed a Memorandum of Understanding (MOU) and has agreed to the terms of a development agreement with a digital assets and crypto wallet creator to produce a gold-backed cryptocurrency coin. AABB is continuing its discussions with the developer to plan the details of the design, branding, implementation and milestone events schedule for the gold-backed crypto coin under the agreed terms prior to initiating the development process. Viewed as a revenue diversification project to create liquidity and monetize gold production, the Company is excited to release further details of the gold-backed crypto coin project next week after the definitive development agreement is completed.

AABB is planning to market its branded gold-backed cryptocurrency coin extensively to large population and high growth markets worldwide including India and China. The economic fundamentals of India’s high demand and interest in physical gold and China’s expanding use of its national digital currency and digital wallets could naturally lend themselves to the future use of a AABB’s gold-backed cryptocurrency coin.

https://finance.yahoo.com/news/peoples-bank-china-early-stage-093000108.html

Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc., is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Guerrero, Mexico, to our client sales networks in Asia. This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Contact the Company at:

Email:                                      [email protected]
Website:                                  www.asiametalsinc.com
Phone:                                     702-866-9054
Parkin Investor Relations
Kevin Parkin

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Asia Broadband Inc.’s (the “Company”) expected current beliefs about the Company’s business, which are subject to uncertainty and change. The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory, market and competitive circumstances change. Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website. The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

• Health spending in Canada
  was
  approximately
  $264 billion
  in 2019, 30%
  represents private-sector spending
  
  ¹
  
  
• One of the
  main pain points for employers and insurers
  is the multiple vendors required to cover the spectrum of healthcare services
• CloudMD delivers one
  centralized platform that addresses
  access to
  primary and specialist care, mental health support,
  and
  educational resources
• The solution provides
  personalized care p
  lans unique to each individual
  through proven systems
  ,
  triage
  ,
  assessment and navigation
• Creates an improved healthcare experience resulting in better outcomes,
  faster adoption rates and increased engagement
• Led by Karen Adams, Global Head
  ,
  Enterprise
  Health
  Solutions,
  an
  industry leader with over 20 years’ experience in enterprise health and wellness

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company revolutionizing the delivery of healthcare to patients, is excited to announce that it has launched an Enterprise Health Solutions Division designed to create engagement and enable patients through personalized health and wellbeing solutions. Karen Adams, Chief Health Innovation Officer will lead the new division and assume the additional role of Global Head of Enterprise Health Solutions. Karen is a subject matter expert in enterprise health and wellness programs and brings over 20 years’ experience developing industry leading mental health and wellness programs for some of the largest corporations and insurers in Canada, including Morneau Shepell and Shepell.fgi.

Karen Adams, Global Head, Enterprise
Health
Solutions commented, “Employers are looking for agile,wellbeing initiatives that positively impact the employee experience.We have been able to acquire organizations who are leaders in mental and physical health. It is evident that employers are looking for programs that recognize the unique needs of each individual and that personalizes their healthcarejourney. Our philosophy is to provide access to better care by leveraging technology to ensure continuity of evidenced based care through a multidisciplinary team-based approach. CloudMD is at the forefront of taking leading value–based care and ensuring that an individual is accessing reliable resources to improve their wellbeing whether they are at work, off work, recovering or returning to work. Our inclusive approach drives employee engagement and will enable employers and employees to thrive.”

In 2019, Health spending in Canada was approximately $264 billion, with 30% representing private-sector spending¹. Furthermore, Canadians spend almost a billion dollars ($950 million) on counselling services each year² and lose approximately $2.1 billion in wages due to long wait times for healthcare services³. Many do not receive the full scope of care they need and end up cycling through the acute care system. As organizations focus on issues relating to equality, diversity, inclusion, and mental health in managing employee health concerns it’s apparent that the way group benefits programs are administered needs to change. In the current system, employers are burdened with a siloed approach to managing health and wellbeing, and are using various stand-alone, single issue solutions to address their employees’ healthcare needs. CloudMD recognizes the market needs to integrate disconnected health and wellbeing benefits with technology enabled services to ensure increased access and continuity of care.

CloudMD will be offering clients a connected system of health solutions that recognizes the unique needs of each person. The program starts with a personal assessment (to determine each employee’s unique social, physical and mental health needs) and designs a personalized navigation care plan. All programs use progressive measurement and evidenced based care which results in better health outcomes. This transformational approach to employee health and wellbeing is enabled through the strategic acquisitions of leading healthcare solutions Re:Function, Snapclarity, HumanaCare, Medical Confidence, and iMD Health. Coupled with CloudMD’s virtual care, primary care and allied health network, the centralized platform creates an integrated solution to help employers address their workforce’s holistic health and wellness. CloudMD’s enterprise health solutions leverage both public and private funding which optimizes employer’s health and wellness spend.

Dr. Essam Hamza, CEO comments, “Our Enterprise Health SolutionsDivision aims to break down the barriers of traditional healthcare by providing one comprehensive platform to address all modalities of health and wellness and offer enterprise clients a ‘one stop shop’ for their employee benefit plans. Our mission is to provide holistic, patient focused care, and through our team-based approach we are able to provide better access to care and a personalized plan that encompasses the patient’s entire healthcare journey.We are revolutionizing the delivery of healthcare and aim to partner with clients to deliver greater value and impact, while optimizing their investment in health and wellness.”

About CloudMD Software & Services

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”

Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:

Julia Becker

VP, Investor Relations

[email protected]

Karen Adams

Global Head, Enterprise
Health
Solutions

[email protected]

Forward Looking Statements

This news release contains forward-looking statements that are based on CloudMD’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

1


https://www.cihi.ca/en/health-spending-in-canada-reaches-264-billion



2 https://cmha.ca/ending-health-care-disparity-canada
3https://www.globenewswire.com/news-release/2020/05/07/2029157/0/en/Fraser-Institute-News-Release-Medical-wait-times-cost-Canadian-patients-more-than-2-billion-in-lost-wages-before-COVID-19.html

Palm Beach, Florida, Nov. 12, 2020 (GLOBE NEWSWIRE) — PMV Consumer Acquisition Corp. (NYSE: PMVC.U) (the “Company”) today announced that, commencing on November 12, 2020, holders of the units (the “Units”) sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock (the “Common Stock”) and warrants (the “Warrants”) included in the units.

The Common Stock and Warrants received from the separated Units will trade on the New York Stock Exchange (“NYSE”) under the symbols “PMVC” and “PMVC WS”, respectively. Units that are not separated will continue to trade on the NYSE under the “PMVC.U” ticker symbol. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Common Stock and Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About PMV Consumer Acquisition Corp.

PMV Consumer Acquisition Corp. is a special purpose acquisition company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to any particular industry or geographic region, although the Company initially intends to focus on target businesses in the consumer industry with enterprise valuations in the range of $200 million to $3.5 billion.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the initial public offering, the anticipated use of the proceeds thereof and the search for an initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements, including those set forth in the risk factors section of the prospectus used in connection with the Company’s initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Contact:

Peter D. Goldstein
Executive Vice President and Secretary
(561) 318-3766

WILMINGTON, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO) will report financial results for its third quarter which ended October 31, 2020 after the market close on Wednesday, December 9, 2020. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results.

What: nCino’s Third Quarter Fiscal Year 2021 Financial Results Conference Call
When: Wednesday, December 9, 2020 at 4:30 p.m. ET
Webcast Link: https://investor.ncino.com/ 

Replay: A webcast replay will be available on the Investor Relations section of nCino’s website following the call. 

About nCino

nCino (NASDAQ: NCNO) is the worldwide leader in cloud banking. The nCino Bank Operating System^® empowers financial institutions with scalable technology to help them achieve revenue growth, greater efficiency, cost savings and regulatory compliance. In a digital-first world, nCino’s single digital platform enhances the employee and client experience to enable financial institutions to more effectively onboard new clients, make loans and manage the entire loan life cycle, and open deposit and other accounts across lines of business and channels. Transforming how financial institutions operate through innovation, reputation and speed, nCino works with more than 1,200 financial institutions globally, whose assets range in size from $30 million to more than $2 trillion. For more information, visit: www.ncino.com.

INVESTOR CONTACT

JoAnn Horne
Market Street Partners
+1 415.445.3240
[email protected] 

MEDIA CONTACT

Natalia Moose, nCino
+1 910.833.0970
[email protected] 

ESCONDIDO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire – CB Scientific. Inc. (OTC:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, is pleased to announce a definitive purchase agreement to acquire Datrix, LLC (Datrix), a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. This acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3 devices.        

Under the terms of the acquisition agreement, Datrix will continue to operate as an OEM manufacturer to its existing customer base and also become the exclusive manufacturer for the next generation of CBSC’s proprietary FDA- and CE-cleared ECG my-Cam Cardiac Event Monitor, including the interactive cloud-based My-Cardia acquisition software and the associated smartphone apps. This acquisition also provides CBSC and its subsidiary My-Cardia (USA) Inc. the opportunity to expand their product offerings quickly with the addition, integration and implementation of Datrix’s wireless Sirona and VX3 devices. The addition of these new products to CBSC’s existing portfolio will now give the Company’s customers several new alternative monitoring/testing choices, which will further help improve earlier remote detection and diagnosis of problematic cardiac rhythms in patients. 

Jon Barron, president and founder of Datrix, LLC, said, “We are enthusiastic about our exciting new partnership with CBSC. They provide a great new platform for us to extend the outreach of our current products, improve and enhance their existing offerings, and expand the design and development of newer device technologies, leading to new avenues for improving the detection of cardiac heart rhythm abnormalities remotely.”

“We are extremely excited about our acquisition of Datrix, LLC and how it enhances and strengthens the growth trajectory of our business,” said Charles Martin, CBSC CEO. “The acquisition, combined with other expansion efforts already underway, will position CBSC to play a significant role in delivering innovative diagnostic devices and testing into this ever-expanding market, further helping our company to establish a solid footprint in the worldwide remote cardiac ambulatory noninvasive ECG monitoring market.”

The acquisition is expected to close during Q4 of fiscal year 2020, subject to customary closing conditions.  Financial terms of the agreement are not being disclosed.

As new developments occur, CB Scientific plans to make further announcements through press releases and regulatory filings to keep its shareholders, industry participants and the public markets informed.

About Datrix, LLC:

Datrix, LLC is a leading global manufacturer and provider of ambulatory ECG devices, established in 1988.  For over 30 years, medical companies, distributors and dealers have partnered with Datrix to design and develop dependable products with the latest technologies and advancements that meet the highest industry standard. Datrix’s approach to quality exceeds today’s requirements through the implementation of lean manufacturing practices. Their Quality Management System is certified to international standards of ISO 13485 and is in compliance with the Quality Systems Regulations of the FDA, with proprietary devices also bearing CE marking for conformity for marketing in the European Union. The manufacturing facility is registered with the FDA. For more information, please visit: www.datrixmed.com.

CB Scientific Inc. Company Contact Information:

340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870

Emails:
General inquires: [email protected]
Investor Inquiries: [email protected]

Company Website and Social Media Outlets:
CB Scientificwebsite, Twitter, Facebook, Instagram and LinkedIn

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.  Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

• Jefferies Virtual London Healthcare Conference
  : John Schroer, chief financial officer, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 a.m. ET.
• Evercore ISI
  HealthCONx
  Conference
  : Ronald Renaud, chief executive officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 2:15 p.m. ET.

A live webcast of the sessions will be accessible through the “Events and Presentations” page of the Company’s website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Contacts for Translate Bio
Investors  Teri Dahlman [email protected] 617-817-8655	Media Maura Gavaghan [email protected] 617-233-1154

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in fireside chats at the Stifel and Jefferies 2020 Virtual Healthcare Conferences.

Details for the presentations are as follows:

• The Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, from 10:40 – 11:10 a.m. ET. Following is a link to access the webcast: https://wsw.com/webcast/stifel27/sbbp/2079792  
• The Jefferies Virtual Healthcare Conference on Thursday, November 19, 2020, from 7:55 – 8:25 p.m. GMT. Following is a link to access the webcast: https://wsw.com/webcast/jeff141/sbbp/1833975

The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Investor Relations

Solebury Trout
Mike Biega
+1 617-221-9660
[email protected]

Corporate
&
Media Relations

Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]